Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL.

Rikhof, B; van der Graaf, W T A; Meijer, C; Le, P T K; Meersma, G J; de Jong, S; Fletcher, J A; Suurmeijer, A J H

Rikhof, B; van der Graaf, W T A; Meijer, C; Le, P T K; Meersma, G J; de Jong, S; Fletcher, J A; Suurmeijer, A J H.

Affiliation

Rikhof B; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Br J Cancer ; 99(10): 1600-6, 2008 Nov 18.

Article in En | MEDLINE | ID: mdl-18941456

Subject(s)

Fas Ligand Protein/therapeutic use; Gastrointestinal Stromal Tumors/metabolism; fas Receptor/biosynthesis; Adult; Aged; Aged, 80 and over; Antineoplastic Agents/pharmacology; Antineoplastic Agents/therapeutic use; Apoptosis/drug effects; Benzamides; Cell Line, Tumor; Female; Gastrointestinal Stromal Tumors/drug therapy; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines/pharmacology; Piperazines/therapeutic use; Pyrimidines/pharmacology; Pyrimidines/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fas Receptor / Gastrointestinal Stromal Tumors / Fas Ligand Protein Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2008 Type: Article Affiliation country: Netherlands

Fulltext

XML

PubMed Links

Search on Google